AAIC
Hospitals Figuring Out How to Incorporate Beta-Amyloid Testing in Standard Clinical Practice
Premium
Spurred by newly available beta-amyloid-targeting drugs, hospitals are exploring how to diagnose Alzheimer's patients early and determine their treatment.
The diagnostic firm's approach involves testing for tau that's bound to small lipid particles known as extracellular vesicles using its APEX platform.
The company drew on data from prior studies and simulations to show what happens when patients stop receiving the beta-amyloid-targeting drug.
Two blood-based biomarkers, percentage of p-tau 217 and amyloid-beta 42/40 ratio, predicted the presence of beta-amyloid plaque in patients' PET scans.
At AAIC, researchers showed the potential of long-term treatments with Roche’s gantenerumab in patients likely to develop dominantly inherited Alzheimer's.